Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Brenton Taylor sold 2,829 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $5.42, for a total transaction of $15,333.18. Following the sale, the executive vice president directly owned 264,978 shares in the company, valued at $1,436,180.76. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Sight Sciences Stock Performance

Shares of SGHT opened at $5.48 on Tuesday. The firm has a 50-day moving average of $4.95 and a 200-day moving average of $5.31. The company has a market cap of $298.17 million, a PE ratio of -7.72 and a beta of 2.38. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.86 and a quick ratio of 5.48. Sight Sciences, Inc. has a one year low of $3.11 and a one year high of $9.24.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. The business had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.46 million. As a group, equities analysts forecast that Sight Sciences, Inc. will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in shares of Sight Sciences in the 1st quarter valued at $128,000. Strs Ohio purchased a new stake in shares of Sight Sciences in the first quarter valued at about $158,000. Rhumbline Advisers lifted its position in shares of Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after buying an additional 4,319 shares in the last quarter. Geode Capital Management LLC boosted its position in Sight Sciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock worth $3,494,000 after purchasing an additional 43,791 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Sight Sciences during the second quarter valued at about $67,000. 55.51% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SGHT. Citigroup boosted their target price on shares of Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Weiss Ratings lowered Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.14.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.